Home
Clinical Trials
Bevacizumab and Oxaliplatin C...

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Last Updated: 2023-07-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

247 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-08

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving bevacizumab together with combination chemotherapy may be a better way to block tumor growth. Studying the amount of an enzyme found in the tumor may help doctors plan the best treatment.

PURPOSE: This randomized phase II trial is studying giving bevacizumab, oxaliplatin, and irinotecan or giving bevacizumab, oxaliplatin, leucovorin, and fluorouracil in treating patients with metastatic or recurrent colorectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab

NCT00720512

Colorectal Cancer

TERMINATED PHASE3

Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00416494

Colorectal Cancer

COMPLETED PHASE2

Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT00467142

Colorectal Cancer

COMPLETED PHASE2

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

NCT00449163

Colorectal Cancer

TERMINATED PHASE2

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01280643

Metastatic Colorectal Cancer

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Compare the response rate (complete and partial), progression-free survival, and overall survival of patients with previously untreated metastatic or locally recurrent colorectal adenocarcinoma with high vs low thymidylate synthase (TS) expression treated with fluorouracil, leucovorin calcium, oxaliplatin, and bevacizumab or irinotecan, oxaliplatin, and bevacizumab.
* Compare the toxicity of these regimens in these patients.
* Correlate gene expression with response rates in patients treated with these regimens.
* Correlate gene expression with toxicity of these regimens in these patients.
* Correlate dihydropyrimidine dehydrogenase, thymidine phosphorylase, and mammalian excision repair cross complementary protein expression with antitumor response in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to thymidylate synthase (TS) expression levels (high vs low or indeterminate). Patients with high TS expression are randomized to 1 of 2 treatment arms (Arms A or B). Patients with low or indeterminate TS expression are assigned to Arm C.

* Arm A: Patients receive bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15.
* Arm B: Patients receive bevacizumab and oxaliplatin as in arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15.
* Arm C: Patients receive bevacizumab, oxaliplatin, leucovorin calcium, and fluorouracil as in arm B.

In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.

Patients are followed up every 3 months for 2 years and then every 6 months for 2 years from the date of study registration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A (High TS, IROX/bev)

Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.

Group Type EXPERIMENTAL

bevacizumab

Intervention Type BIOLOGICAL

Given IV

irinotecan hydrochloride

Intervention Type DRUG

Given IV

Oxaliplatin

Intervention Type DRUG

Given IV

Arm B (High TS, FOLFOX/bev)

Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.

Group Type EXPERIMENTAL

bevacizumab

Intervention Type BIOLOGICAL

Given IV

fluorouracil

Intervention Type DRUG

Given IV

leucovorin calcium

Intervention Type DRUG

Given IV

Oxaliplatin

Intervention Type DRUG

Given IV

Arm C (Low or intermediate TS, FOLFOX/bev)

Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.

Group Type EXPERIMENTAL

bevacizumab

Intervention Type BIOLOGICAL

Given IV

fluorouracil

Intervention Type DRUG

Given IV

leucovorin calcium

Intervention Type DRUG

Given IV

Oxaliplatin

Intervention Type DRUG

Given IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab

Given IV

Intervention Type BIOLOGICAL

fluorouracil

Given IV

Intervention Type DRUG

irinotecan hydrochloride

Given IV

Intervention Type DRUG

leucovorin calcium

Given IV

Intervention Type DRUG

Oxaliplatin

Given IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NSC 704865, RhuMAb VEGF, Recombinant Humanized Monoclonal Anti-VEGF Antibody 5-Fluorouracil, 5-FU, Adrucil, Efudex Camptothecin-11, CPT-11, Camptosar Leucovorin, Wellcovorin' citrovorum factor, folinic acid, 5-formyl tetrahydrofolate, LV, LCV. Eloxatin, trans-l-diaminocyclohexane oxalatoplatinum, cis-[oxalato(trans-l-1,2-diaminocyclohexane)platinum(II)].

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Metastatic or locally recurrent colorectal adenocarcinoma
* Measurable disease
* At least 2 formalin-fixed paraffin embedded core needle biopsies OR fine needle aspirate containing a minimum of 3 clusters of malignant cells and fixed tissue from the previous biopsy
* If no tissue samples are available the patient must be willing to undergo biopsy of a metastatic site
* Age 18 and over
* Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Prothrombin time (PT)/international normalized ratio (INR) ≤ 1.5 unless patient is receiving full-dose anticoagulants AND the following criteria are met:

* In-range INR (usually between 2 and 3) AND on a stable dose of warfarin or low molecular weight heparin
* No active bleeding or pathological condition that is associated with a high risk of bleeding
* Partial thromboplastin time (PTT) \< 1.5 times upper limit of normal (ULN)
* Alanine transaminase (ALT) and aspartate aminotransferase (AST) \< 3 times ULN
* Bilirubin ≤ 1.5 times ULN
* Creatinine ≤ 1.8 mg/dL
* Meets 1 of the following criteria:

* Protein negative on urine dipstick
* Urine protein/creatinine ratio \< 1.0
* Less than 2 g protein on 24-hour urine collection
* Patients with a history of hypertension must meet the following criteria:

* Blood pressure \< 150/90 mm Hg
* Stable regimen of anti-hypertensive therapy
* More than 28 days since prior major or open surgery
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after study participation
* Prior non-colorectal malignancies are allowed provided the following criteria are met:

* No current clinical evidence of persistent or recurrent disease
* No active therapy for non-colorectal malignancy, including hormonal therapy

EXCLUSION:

* Pregnant or nursing
* Arterial thromboembolic events within the past 6 months, including the following:

* Transient ischemic attack
* Cerebrovascular accident
* Unstable angina pectoris
* Myocardial infarction
* Symptomatic arrhythmia
* Symptomatic congestive heart failure
* Clinically significant peripheral artery disease
* New York Heart Association class III or IV heart disease
* Serious nonhealing wound, ulcer, or bone fracture within the past 28 days
* Significant traumatic injury within the past 28 days
* Neuropathy ≥ grade 2
* Ongoing or active infection
* Concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)
* Prior chemotherapy for metastatic disease. Adjuvant therapy completed at least 12 months before first evidence of metastasis allowed
* Cardiovascular, renal, hepatic, or other nonmalignant systemic disease that would preclude study therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Neal J. Meropol, MD

Role: STUDY_CHAIR

Fox Chase Cancer Center

Jean L. Grem, MD

Role: STUDY_CHAIR

University of Nebraska

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

California Cancer Care, Incorporated - Greenbrae

Greenbrae, California, United States

Site Status

Aurora Presbyterian Hospital

Aurora, Colorado, United States

Site Status

Boulder Community Hospital

Boulder, Colorado, United States

Site Status